Product Information
ALLOPURINOL 300 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.0522 per EA under NDC 00904657261. Its NADAC has been published 501 times since Mar 1, 2017.
FDA first approved this application on Jun 27, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904657261
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALLOPURINOLApproval Type
Generic (ANDA)
FDA Application
ANDA075798FDA Approved
6/27/2003
TE Code
AB
On Market Since
6/27/2003
Pharmacological Classes
Price Statistics
The NADAC for ALLOPURINOL 300 MG TABLET has been published 501 times since Mar 1, 2017, and over the history we have for it it has declined 79.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0522 per EA |
|---|---|
| All-time high | $0.2558 (Mar 15, 2017) |
| All-time low | $0.0522 (Sep 23, 2026) |
| 52-week high | $0.0652 |
| 52-week low | $0.0522 |
| Median price | $0.0884 |
| Average price | $0.1033 |
| Largest weekly change | -17.2% (Dec 20, 2017) |
| Weeks tracked | 501 |
| Tracking since | Mar 1, 2017 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
allopurinol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALLOPURINOL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALLOPURINOL 300 MG TABLET, manufactured by Major Pharmaceuticals, is $0.0522 per EA (NDC 00904657261), effective Sep 30, 2026.
How has the price of ALLOPURINOL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALLOPURINOL 300 MG TABLET has declined 79.6%. It has been tracked across 501 weekly CMS publications since Mar 1, 2017.
What are the highest and lowest recorded NADAC prices for ALLOPURINOL 300 MG TABLET?
Since Mar 1, 2017, the NADAC for ALLOPURINOL 300 MG TABLET has ranged from a low of $0.0522 (Sep 23, 2026) to a high of $0.2558 (Mar 15, 2017), with a median of $0.0884 per EA.
Are there cheaper alternatives to ALLOPURINOL 300 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ALLOPURINOL 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ALLOPURINOL 300 MG TABLET?
ALLOPURINOL 300 MG TABLET (NDC 00904657261) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.